282 related articles for article (PubMed ID: 27022024)
1. Modeling the Etiology of p53-mutated Cancer Cells.
Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
[TBL] [Abstract][Full Text] [Related]
2. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
Aziz MH; Shen H; Maki CG
Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
[TBL] [Abstract][Full Text] [Related]
4. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
[TBL] [Abstract][Full Text] [Related]
5. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
[TBL] [Abstract][Full Text] [Related]
6. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
7. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.
Abrams SL; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Libra M; Falzone L; Candido S; Montalto G; Cervello M; Lombardi P; McCubrey JA
Adv Biol Regul; 2022 Jan; 83():100840. PubMed ID: 34866036
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
9. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
10. Nutlin-3a selects for cells harbouring TP53 mutations.
Kucab JE; Hollstein M; Arlt VM; Phillips DH
Int J Cancer; 2017 Feb; 140(4):877-887. PubMed ID: 27813088
[TBL] [Abstract][Full Text] [Related]
11. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
12. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
[TBL] [Abstract][Full Text] [Related]
13. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
[TBL] [Abstract][Full Text] [Related]
14. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
15. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
[TBL] [Abstract][Full Text] [Related]
16. MDM2 Antagonist Nutlin-3 Stimulates Global DNA Hydroxymethylation by Enhancing p53-TET1 Signaling Axis.
Wu D; Li Y; Li C; Zhong S; Liu B; Hang H; Wang H
ACS Chem Biol; 2023 Oct; 18(10):2240-2248. PubMed ID: 37463352
[TBL] [Abstract][Full Text] [Related]
17. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.
Davaadelger B; Shen H; Maki CG
PLoS One; 2014; 9(11):e110844. PubMed ID: 25380055
[TBL] [Abstract][Full Text] [Related]
18. Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction.
Wang X; Magdziarz P; Enriquez E; Zhao W; Quan C; Darabedian N; Momand J; Zhou F
Anal Biochem; 2019 Mar; 569():53-58. PubMed ID: 30721669
[TBL] [Abstract][Full Text] [Related]
19. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
Duan L; Perez RE; Lai X; Chen L; Maki CG
J Biol Chem; 2019 Jun; 294(23):9186-9197. PubMed ID: 31036564
[TBL] [Abstract][Full Text] [Related]
20. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]